By NewsDesk  @bactiman63 Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120...

Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced this week that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing...

By NewsDesk  @infectiousdiseasenews Singapore’s Health Sciences Authority (HSA) announced today granting conditional approval for Gilead Sciences Singapore Pte Ltd’s (Gilead) Veklury® (remdesivir). This...

The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose,...

The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17....

Gilead Sciences, Inc. announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic...

First regimen to treat all six major HCV genotypes The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced...